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Abstract 
Background 
%RWKW\SHGLDEHWHV7'0DQG%ȕ/\VYDULDQWRIILEULQRJHQDUHDVVRFLDWHGZLWKGHQVH
fibrin clots, impaired fibrinolysis and increased cardiovascular risk.  
Objectives 
IQYHVWLJDWHZKHWKHU%ȕ$UJ/\VDGGVWRYDVFXODUULVNE\PRGXODWLQJILEULQQHWZRUN
structure and/or fibrinolysis in diabetes. The primary aim was to study effects of 
%ȕ$UJ/\VRQILEULQQHWZRUNFKDUDFWHULVWLFVLQ7'06HFRQGDU\DLPVLQYHVWLJDted 
LQWHUDFWLRQVEHWZHHQJHQGHUDQG%ȕ$UJ/\VVXEVWLWXWLRQLQUHODWLRQWRILEULQFORWSURSHUWLHV
and vascular disease. 
Patients/Methods 
*HQRW\SLQJIRU%ȕ$UJ/\VDQGG\QDPLFFORWVWXGLHVZHUHFDUULHGRXWRQ7'0
patients enrolled in the Edinburgh Type 2 Diabetes Study. Turbidimetric assays of individual 
plasma samples analysed fibrin clot characteristics with additional experiments conducted 
on clots made from purified fibrinogen, further examined by confocal and electron 
microscopy. 
Results  
Plasma FORWO\VLVWLPHLQ%ȕ/\VZDVORQJHUWKDQ%ȕ$UJYDULDQWmean±SD; 763±322 
and 719±351 s, respectively; p<0.05). Clots made from plasma-purified fibrinogen of 
individuals with Arg/Arg, Arg/Lys and Lys/Lys genotypes showed differences in fibre 
thickness (46.75±8.07, 38.40±6.04 and 25±4.99 nm, respectively; p<0.001) and clot lysis 
time (419±64, 442±87 and 517±65 s, respectively; p=0.02), directly implicating the 
SRO\PRUSKLVPLQWKHREVHUYHGFKDQJHV:RPHQZLWK%ȕ/\VJHQRW\SHKDGLQFUHDVHGULVN
RIFHUHEURYDVFXODUHYHQWVDQGZHUH\RXQJHUFRPSDUHGZLWK%ȕ$UJYDULDQW2±4.0 and 
68.2±4.4 years, respectively; p=0.035). 
Conclusions 
)LEULQRJHQ%ȕ/\VYDULDQWLVDVVRFLDWHGZLWKWKURPERWLFILEULQFORWVLQGLDEHWHV 
independently of traditional risk factors. Prospective studies are warranted to fully 
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XQGHUVWDQGWKHUROHRI%ȕ$UJ/\VLQSUHGLVSRVLWLRQWRYDVFXODULVFKDHPLDLQ7'0ZLWK 
the potential to develop individualised antithrombotic management strategies. 
 
Keywords: Diabetes Mellitus, Fibrinogen, Genetic Polymorphism, Thrombosis, Vascular 
Diseases 
What is known on this 
topic 
x The common genetic variant of fibrinogen BBArg448Lys 
is associated with significant changes in clot structure 
and fibrinolysis. 
x Diabetes is associated with qualitative and quantitative 
changes in coagulation proteins, resulting in dense fibrin 
networks that are difficult to lyse.  
What this paper adds x We demonstrate WKDW%ȕ/\VYDULDQWRIILEULQRJHQLV
associated with thrombotic fibrin networks in a highly 
complex and multifactorial condition such as type 2 
diabetes.  
x Our data also suggest an adverse clinical vascular effect 
of this polymorphism in diabetes, which may be gender 
specific. 
x Further clinical studies are needed to investigate the role 
of this common polymorphism in vascular risk in 
diabetes, which may lead to individualised therapies 
aiming to reduce cardiovascular events, the main cause 
of mortality in this population. 
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Introduction 
Despite advances in medical therapy, cardiovascular complications remain the main 
cause of mortality in diabetes. In addition to increased risk of a first atherothrombotic event, 
prognosis following vascular ischaemia remains poor, in contrast to individuals without 
diabetes, in whom clinical outcome has improved over the past decade (1-7). Current 
evidence indicates that the adverse clinical outcome in diabetes following vascular 
ischaemia is due to more extensive vascular pathology, increased thrombosis potential and 
high prevalence of heart failure, the latter being partly related to atherothrombotic 
complications (1-4;8).  
The prothrombotic environment in diabetes plays a key role in increased 
cardiovascular risk in this population. Formation of an obstructive thrombus in a diseased 
vessel occurs secondary to complex interactions between the cellular and protein phase of 
coagulation (reviewed in (5)). The thrombus, or blood clot, is composed of a backbone of 
fibrin fibres, with embedded platelets and blood cells. Diabetes is associated with qualitative 
and quantitative changes in procoagulant and anti-fibrinolytic proteins leading to fibrin clots 
with tight network structure and resistance to lysis, a structure that has been associated with 
increased cardiovascular risk (6;7;9-17). Moreover, we have recently shown gender 
differences in the association of fibrin network structure with metabolic and cardiovascular 
factors, suggesting a differential fibrin-related thrombosis risk in men and women with 
diabetes (18). 
)LEULQRJHQ%ȕ$UJ8Lys, a common genetic polymorphism of which the Lys448 
allele has a frequency of 15% to 20% in whites, is associated with both increased vascular 
risk and hypofibrinolysis (9;19-22). Using recombinant techniques, we have previously 
shown that clots made fURPWKH%ȕ/\VYDULDQWRIILEULQRJHQKDYHDFRPSDFWVWUXFWXUHRI
thin fibres and small pores, with increased stiffness and greater resistance to lysis (9), 
consequently predisposing to a thrombotic environment.  
7DNHQWRJHWKHUERWKGLDEHWHVDQG%ȕ$UJLys variants of fibrinogen induce 
changes in fibrin networks that are associated with increased cardiovascular risk. Despite 
 5 
 
WKHUHODWLYHO\KLJKSUHYDOHQFHRIGLDEHWHVDQG%ȕ$UJ/\VSRO\PRUSKLVPWKHHIIHFWRI
%ȕ$UJ/\VRQFORWVWUXFWXUHLQGLDEHWHVUHmains unknown. Therefore, the primary aim of 
WKLVVWXG\ZDVWRLGHQWLI\ZKHWKHU%ȕ$UJ/\VKDVDQLQGHSHQGHQWHIIHFWRQWKHILEULQ
network in individuals with type 2 diabetes (T2DM). Our secondary aims included the 
analysis of potential gender differences RI%ȕ$UJWR/\VVXEVWLWXWLRQRQFORW
characteristics and the preliminary investigation of the clinical vascular effect of this 
polymorphism in diabetes. 
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Materials and Methods 
 
Study population and genotyping 
The study protocol of the Edinburgh Type 2 Diabetes Study (ET2DM) has been 
described elsewhere (23). Briefly, 1,066 patients with T2DM (age 60±75 years) were 
recruited from a population-based register including patients treated in both primary and 
secondary care after informed consent. The study population has been shown previously to 
be largely representative of all those randomly selected to participate (N=5,454). A total of 
822 plasma samples were available for genotyping and clot structure analysis. 
Blood samples were taken into tubes containing 1ml 0.109M tri-sodium citrate  
anticoagulant to a final volume of 10ml without a tourniquet after a 4-hour fast, usually at 
midday. The first 5ml were used for clinical tests and platelet-poor plasma was separated 
from subsequent samples. Blood was centrifuged at 2,400g for 20 minutes at room 
temperature and plasma was aspirated. DNA was purified from blood samples and 
JHQRW\SLQJIRU%ȕ$UJ/\VYDULDQWVRIILEULQRJHQwas performed as previously described 
(24). 
 
Analysis of fibrinogen levels, plasma clot formation and lysis 
Fibrinogen levels and fibrin clot characteristics were measured in the 822 plasma 
samples, as previously described (18). Plasma levels of fibrinogen were studied by Clauss 
assay. Clot structure/fibrinolysis was assessed by turbidimetric assays. 
 
Fibrinogen purification 
Plasma samples were chosen for each variant (Arg/Arg, Arg/Lys and Lys/Lys; n=12 
samples for each group), which were matched for sex and glycaemic control, measured as 
HbA1C, and pooled. Fibrinogen was purified by affinity chromatography using a calcium-
dependent IF-1 monoclonal antibody and an automated chromatography system, as 
described (9). Samples were dialysed against 100mM NaCl, 50mM Tris, pH 7.4 using 
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dialysis cellulose membrane tubing, size 10 x 6mm, for 2 hours and subsequently overnight. 
Integrity and purity of plasma-purified fibrinogen were analysed by sodium dodecyl sulphate 
(SDS)-polyacrylamide gel electrophoresis (PAGE). Fibrinogen concentration was determined 
and adjusted to a dilution of 1 mg/ml. Four replicates were performed for each variant and 
experiments were repeated on three different occasions. Results are presented as 
mean±standard deviation (SD). 
 
Analysis of clot formation and lysis in a purified system 
A total of 50µl of purified fibrinogen was mixed with 50µl lysis mix (FXIII [ZLB 
Behring] and plasminogen [ERL] in 100mM NaCl, 50mM Tris, pH 7.4). Polymerisation and 
lysis were initiated by the addition of 50µl clotting mix (thrombin [Millipore] and tissue 
plasminogen activator [Technoclone] in 7.5mM CaCl2, 100mM NaCl, 50mM Tris, pH 7.4), at 
ambient temperature in a 96-well plate. Final concentrations in the fibrinogen, clotting and 
lysis mix were 333µg/ml fibrinogen, 22µg/ml FXIII, 25µg/ml plasminogen 0.5U/ml thrombin 
and 0.312µg/ml tissue plasminogen activator. Four replicates were performed for each 
variant and experiments were repeated on 3 different occasions. Increase in turbidity at 
340nm was continuously monitored every 12 seconds on an ELx-808 IU ultramicroplate 
reader over a period of 120 minutes.  
 
Laser scanning confocal microscopy 
Plasma purified fibrinogen (30 µl) was used in the presence of 0.025mg/ml 488 
fluorescent-labelled fibrinogen. Clotting was initiated with 5µl of activation mix (containing 
thrombin in 35mM CaCl2, 50mM Tris, 100mM NaCl, pH 7.4), to the fibrinogen solution. Final 
concentrations in the clotting mix were 400µg/ml fibrinogen and 0.05U/ml thrombin. 
Subsequently, 30µl of this mixture was pipetted into Ibidi slides in duplicate. Clots were 
visualised using Leica TCS SP-2 laser scanning confocal equipment on an inverted DM IRE 
2 microscope with 40x/1.3 oil pH 3 objective lens. At least three areas of 512 x 512 pixels 
were characterised per sample. 
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Electron Microscopy 
3XULILHGILEULQRJHQȝOZDVFORWWHGXSRQDGGLWLRQRIORIDFWLYDWLRQPL[
(containing thrombin in 2.5mM CaCl2, 50mM Tris, 100mM NaCl, pH 7.4), to the fibrinogen 
solution in specially devised small, perforated plastic vessels. Final concentrations in the 
clotting mix were 450µg/ml fibrinogen and 0.5U/ml thrombin. Plasma was diluted 1:2 in 
50mM Tris, 100mM NaCl, pH7.4 and clotted with 5µl 0.05M CaCl2, 11U/ml thrombin in 
50mM Tris, 100mM NaCl, pH 7.4. Samples were incubated at room temperature in a moist 
chamber for 2 hours, washed with sodium cacodylate buffer (0.078M cacodylic acid, pH 7.4) 
and subsequently fixed overnight in 2% glutaraldehyde. Clots were recovered and further 
processed by a stepwise dehydration with an acetone gradient and sputter coated with 
platinum palladium in a 208 HR high-resolution sputter coater. Samples were viewed and 
photographed using a field-emission scanning electron microscope (LEO1530 FEGSEM, 
Leo Electron Microscopy) in 3 different areas of each clot. Images were captured using Leo 
32 version 03.0210 software and cropped using Paintshop Pro version 8.0. Fibre diameters 
of all clots were measured with image analysis software package ImageJ 1,23y (National 
Institutes of Health).  
 
Statistical analysis and power calculations 
Exploratory analysis was done using SPSS program version 16. Between-group 
comparisons of normally distributed variables were carried out using t-test, non-normally 
distributed variables were log-transformed before a t-test was carried out. For plasma 
purified samples, where three genotypes were compared, an ANOVA was carried out. Post-
hoc t-tests were then used to report p-values between two groups. The R environment for 
statistical computing was used to fit logistic regression models to identify associations 
EHWZHHQ%ȕ$UJ/\VSRO\PRUSKLVPDQGYDVFXODUGLVHDVHThe effect of predictors in the 
regression model was characterised using 95% confidence intervals for the odds ratio 
coefficients.   
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Previous work has shown that 10% prolongation in clot lysis time is associated with 
atherothrombotic conditions (18;25;26). To detect a 10% increase in clot lysis time with 
%ȕ/\VYDULDQWVRIILEULQRJHQVDPSOHVZHUHUHTXLUHGJLYHQWKHVWDQGDUGGHYLDWLRQRI
the response variable in our cohort of 56% (at p<0.05 with a power of 80%). Given that the 
IUHTXHQF\RI%ȕ/\VYDriant of fibrinogen in our population of 31%, a total of 790 samples 
were required for analysis. Therefore, our cohort of 822 patients has enough power to detect 
a 10% increase in clot lysis time with %ȕ/\VYDULDQWRIILEULQRJHQ 
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Results 
Patient characteristics 
Clinical characteristics of patients are described in Table I. The distribution of the three allelic 
fibrinogen variants was as expected; the majority of patients had the Arg/Arg variant 
(n=564), with fewer patients (n=234) having the Arg/Lys, and 24 patients possessing the 
Lys/Lys variant. 
Cardiometabolic risk factors, including blood pressure, body-mass index, waist 
circumference, waist/hip ratio, HbA1c and lipid profile were similar in individuals with the two 
variants of fibrinogen. Treatment was also similar when comparing individuals with 
%ȕ$UJDQG%ȕ/\VJHQRW\SHVRIILEULQRJHQVXPmarised in Table I). 
 
%ȕ$UJ/\VDQGSODVPD-derived clots 
%ȕ/\VLVDVVRFLDWHGZLWKFKDQJHVLQFORWVWUXFWXUHDQGILEULQRO\VLV 
Clot maximum absorbance iQFDUULHUVRI%ȕ/\VZDVKLJKHUWKDQ%ȕ$UJ0.37±0.10 
and 0.35±0.10 arbitrary units (au), respectively; p=0.03) and lysis time longer (763±322 and 
719±351 s, respectively; p=0.01). There was no significant difference in lag time between 
%ȕ$UJDQG%ȕ/\VSODVPD125 and 523±116 s, respectively; p=0.70). Results 
are summarised in Figure 1A±C. 
 
%ȕ/\VLVDVVRFLDWHGZLWKKLJKHUILEULQRJHQOHYHOVWKDQ %ȕ$UJ 
)LEULQRJHQOHYHOVZHUHKLJKHULQLQGLYLGXDOVZLWK%ȕ/\VYDULDQWZKHQFRPSDUHGZLWK
%ȕ$UJRYHUWKHZKROHJURXS74 and 3.59±0.73 mg/ml, respectively; p=0.03). 
When split by gender, this difference was only significant in women at 3.81±0.70 and 
3.70±0.70 PJPOIRU%ȕ/\VDQG%ȕ$UJUHVSHFWLYHO\p=0.01), with no difference 
detected in males (3.52±0.69 and 3.49±0.73 mg/ml, respectively; p=0.67).  
The differences in lysis time and maximum absorbance between the two variants were still 
significant after adjusting for fibrinogen levels in the whole group (p=0.03 and 0.009 
 11 
 
respectively). Therefore, the differences in lysis time and clot density are unlikely to be due 
to altered fibrinogen levels comparing the two variants of fibrinogen. 
 
%ȕ$UJ/\VDQGILEULQRJHQ-derived clots  
%ȕ/\VLVDVVRFLDWHGZLWKGHFUHDVHGmaximum turbidity and impaired lysis 
To further investigate the effects of the polymorphism on clot structure/lysis in the absence 
of other plasma proteins, and in order to control for fibrinogen plasma levels, we undertook 
turbidity and lysis analysis of clots made from pools of Arg/Arg, Arg/Lys and Lys/Lys variants 
of fibrinogen. Purity and integrity of fibrinogen preparations prior to experiments were 
confirmed by SDS-PAGE.  
 
Maximum absorbance. Clot maximum absorbance significantly differed between Arg/Arg, 
Arg/Lys and Lys/Lys fibrinogen variants (p=0.003). Clot maximum absorbance of Arg/Arg 
fibrinogen was significantly greater than Arg/Lys or Lys/Lys fibrinogen (0.0357±0.007, 
0.0321±0.005 and 0.0297±0.004 au, respectively; p=0.05 and 0.001 respectively). Although 
maximum turbidity of clots made from Arg/Lys variant appeared greater than that of Lys/Lys 
fibrinogen, the difference failed to reach statistical significance (p=0.09; Figure 2A).  
 
Fibrinolysis. Lysis time increased in a stepwise manner in clots made from Arg/Arg, Arg/Lys 
and Lys/Lys variants (419±64, 442±87 and 517±65 s, respectively, p=0.02). This difference 
was only significant between Arg/Arg and Lys/Lys fibrinogen (p=0.003), and Arg/Lys and 
Lys/Lys (p=0.05) as shown in Figure 2B.  
 
%ȕ/\VLVDVVRFLDWHGZLWKFRPSDFWFORWVDQGWKLQQHUILEULQILEUHV 
Confocal microscopy. Fibrin networks in hydrated clots made from purified Lys/Lys 
fibrinogen were more compact than those of Arg/Lys or Arg/Arg fibrinogen (Figure 3A). Clot 
density was further assessed using an in-house developed computer macro. Fibrin network 
density significantly differed between Arg/Arg, Arg/Lys and Lys/Lys fibrinogen variants 
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(p<0.001). Fibrin network made from purified Arg/Arg fibrinogen was less dense compared 
with Arg/Lys or Lys/Lys (104±31, 496±60 and 434±50 au, respectively; p<0.001). There was 
no significant difference in clot density between Arg/Lys and Lys/Lys (p=0.2). 
 
Scanning electron microscopy. This technique was employed to study clot ultrastructure and 
fibrin fibre thickness. The more compact clot structure in the presence of Lys allele was 
confirmed, which was also associated with thinner fibres. Fibre thickness significantly 
differed between Arg/Arg, Arg/Lys and Lys/Lys fibrinogen variants (p<0.001). Fibre thickness 
of clots made from purified Arg/Arg, Arg/Lys and Lys/Lys variants was 46.75±8.07, 
38.40±6.04 and 25±4.99 nm, respectively; p<0.001 between all variants (Figure 3B,C) 
consistent with the turbidimetric data presented above (Figure 2A). Similar observations 
were made for plasma samples; fibre thickness of clots made from plasma Arg/Arg, Arg/Lys 
and Lys/Lys variants was 49.76±8.19, 32.08±6.21 and 24.04±6.38 nm, respectively; p<0.001 
by ANOVA and between all variants. 
 
The clinical role of %ȕ$UJ/\VYDULDQWVRIILEULQRJHQ 
%ȕ$UJ/\VDQGDJH 
0HDQDJHRIVXEMHFWVZLWK%ȕ/\VZDVORZHUFRPSDUHGZLWK%ȕ$UJDFURVVWKHZKROH
group (67.6±4.1 and 68.3±4.2 years, respectively; p=0.02). This age difference was only 
significant in women (67.2±4.0 and 68.2±4.4 years, respectively; p=0.04) and not men 
(67.9±4.23 and 68.4±4.0 years, respectively; p=0.34). Results are summarised in Figure 4. 
There was no significant difference in age between males and females across the whole 
group (68.2±4.1 and 67.9±4.3 years, respectively; p=0.24). 
 
%ȕ$UJ/\VDQGKLVWRU\RIYDVFXODULVFKDHPLD 
,QWKHZKROHJURXSWKH%ȕ/\VYDULDQWZDVDVVRFLDWHGZLWKSUHYLRXVFHUHEURYDVFXODU
incidents and transient ischaemic attacks (odds ratio [OR], 95% confidence interval [CI] 1.87, 
1.13±3.11; p=0.015; n=822). This value was evident even after adjusting for traditional risk 
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factors, including total cholesterol, high-density lipoprotein, cholesterol, HbA1c, blood 
pressure and smoking (OR, 95% CI 1.98, 1.16±3.37; p=0.016). When the group was split by 
JHQGHUWKHDVVRFLDWLRQRI%ȕ/\VYDULDQWIRUVWURNHWUDQVLHQWLVFKDHPLFDWWDFNZDVRQO\
significant in females and not males, whether adjusted (OR, 95% CI 4.18, 1.56±11.22; p 
=0.003 female: OR, 95% CI  1.43, 0.74±2.76; p=0.27 male) or unadjusted (OR, 95% CI 3.69, 
1.49±9.13; p=0.0045 female: OR, 95% CI 1.38, 0.73±2.62; p=0.32 male). Data are 
summarised in Figure 5.  
1RDVVRFLDWLRQEHWZHHQ%ȕ$UJ/\VSRO\PRUSKLVPDQGDKLVWRU\RIFRURQDU\DUWHU\
disease or myocardial infarction was detected in the whole population or when men and 
women were analysed separately. 
 
%ȕ$UJ/\VDQGFXUUHQWYDVFXODUSDWKRORJ\ 
&DURWLGLQWLPDPHGLDWKLFNQHVVZDVVLPLODULQFDUULHUVRI%ȕ$UJDQG%ȕ/\VYDULDQWV
(1.00±0.23 and 1.04±0.32 mm, respectively; p=0.08), as was ankle-brachial index (ABI) 
(1.00±0.23 and 0.97±0.32, respectively; p=0.09).  
:KHQDQDO\VHGE\JHQGHULQWUDPXUDOWKLFNQHVV,07ZDVVLPLODULQFDUULHUVRI%ȕ$UJ
DQG%ȕ/\VLQPDOHV34 and 1.05±0.34 mm, respectively; p=0.14) and females 
(1.01±0.33 and 1.04±0.23 PPUHVSHFWLYHO\S $%,ZDVVLPLODULQFDUULHUVRI%ȕ$UJ
DQG%ȕ/\VLQPDOHV7 and 0.98±0.228, respectively; p=0.84) but a difference 
was detected in females (1.01±0.16 and 0.95±0.23, respectively; p=0.03).  
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Discussion 
Diabetes, a prothrombotic condition, is associated with compact fibrin networks and 
resistance to fibrinolysis, which contribute to the increased risk of vascular events in this 
population2XUZRUNLVWKHILUVWVWXG\WRLQYHVWLJDWHWKHIXQFWLRQDOUROHRI%ȕ$UJ/\V
variants of fibrinogen in individuals with T2DM and we demonstrate an additional effect of 
this polymorphism on clot structure and fibrinolysis.  
There are a number of novel observations emerging from this work in relation to 
LQGLYLGXDOVZLWK7'0LFDUULHUVRI%ȕ/\VYDULDQWRIILEULQRJHQGLVSOD\FRPSDFWSODVPD
FORWVDQGLPSDLUHGILEULQRO\VLVFRPSDUHGZLWK%ȕ$UJLLLQDSXULILHGV\VWHP%ȕ/\VLV
associated with thinner fibrin fibres and trends in impaired fibrinolysis compared with 
%ȕ$UJ supporting a direct role of this polymorphism in changes observed with plasma 
FORWVLLLDQDVVRFLDWLRQEHWZHHQ%ȕ/\VYDULDQWRIILEULQRJHQDQGSODVPDSURWHLQOHYHO
was evident but only in women, and LYFDUULHUVRI%ȕ/\VYDULDQWZHUH\RXQJHU
suggesting early mortality in this group, which may be gender-specific and attributable to 
increased risk of vascular events. 
An inherent difficulty in studying the functional efIHFWVRI%ȕ/\VYDULDQWRQFORW
structure and lysis is the association of this polymorphism with plasma fibrinogen levels (20). 
This is believed to be related to linkage disequilibrium of the -448G/A polymorphism with -
455 G/A and -148 C/T polymorphisms of the ȕ fibrinogen gene, which determine protein 
levels, lying in the ¶IODQNLQJUHJLRQDQG SURPRWHUUHJLRQRIWKHȕ-chain of fibrinogen, 
respectively,QWKHSUHVHQWZRUNWKHDVVRFLDWLRQEHWZHHQ%ȕ/\VDQGILEULQRJHQOHYHOV
was only evident in women, indicating that environmental factors have stronger effects on 
fibrinogen levels than the %ȕArg448Lys polymorphism in men with T2DM. Therefore, the 
genetic influence on thrombosis risk can differ in men and women with T2DM, which may 
have future therapeutic implications. 
When plasma samples were studied, clot density was higher and lysis time longer in 
LQGLYLGXDOVZLWK%ȕ/\VFRPSDUHGZLWK%ȕ$UJYDUiant. Although fibrinogen levels were 
KLJKHULQFDUULHUVRI%ȕ/\VFRUUHFWLRQIRUSURWHLQOHYHOVGLGQRWDIIHFWWKHUROHRIWKH
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polymorphism on clot density or lysis time, suggesting a direct effect of the polymorphism on 
fibrin structure and fibrinolysis. To confirm that the observed changes in clot structure/lysis 
ZLWK%ȕ/\VYDULDQWRIILEULQRJHQDUHQRWUHODWHGWRDOWHUHGSODVPDSURWHLQOHYHOVZHKDYH
undertaken experiments in a purified system and have shown that clot maximum 
absorbance decreases ZLWKLQFUHDVLQJQXPEHURIFRSLHVRIWKH%ȕ/\VDOOHOH7KLVIXUWKHU
supports the role of this polymorphism in altered clot structure in individuals with T2DM. 
These turbidimetric data were reinforced by confocal and electron microscopy, showing 
increasing density of the fibrin clot and decreasing fibre thickness with increasing copies of 
WKH%ȕ/\VDOOHOH3UHYLRXVZRUNXVLQJDUHFRPELQDQWV\VWHPKDVVKRZQWKLQQHUILEULQ
ILEUHVZLWK%ȕ/\VYDULDQWRIILEULQRJHQEXWLWZDVXQFOHDUZKHWKHUFDUU\LQJRQe allele 
results in an intermediate phenotype, which is demonstrated in this study. Collectively, these 
results confirm the observed changes in plasma clot structure are independent of fibrinogen 
levels and that the genetic variant of fibrinogen studied has an additive effect on the fibrin 
network in individuals with T2DM. Although these findings have potential clinical 
implications, a further limitation of assessing plasma fibrin networks ex vivo to be 
acknowledged is that it ignores the potential influence of platelets, endothelial, or smooth 
muscle cells on clot properties. 
Despite similarities in clot structure using purified and recombinant proteins, clot lysis 
outside the plasma environment showed some inconsistencies. In our previous study, using 
recombinant protein, the difference in clot lysis between the two variants was only evident in 
the plasma environment (9). In contrast, our current study shows differences in clot lysis 
made from the different variants of fibrinogen in the absence of plasma proteins. There are a 
number of possible explanations for this discrepancy. The current work used purified 
fibrinogen, which may have been contaminated with small quantities of plasma proteins not 
detected by SDS-PAGE. Another explanation is related to diabetes-induced post-
translational modifications in fibrinogen that affect clot structure and fibrinolysis (7;27). A 
differential glycation, or other modification such as oxidation, may have occurred in the two 
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variants, resulting in altered clot lysis, particularly as lysine residues are amenable to such 
modifications (28).  
 
2QHREVHUYDWLRQIURPRXUZRUNVXJJHVWVWKDWWKH%ȕ/\VYDULDQWLVDVVRFLDWHG
ZLWKDGYHUVHFOLQLFDORXWFRPHDVLQGLYLGXDOVZLWK%ȕ/\VYDULDQWZHUHVLJQLILFDQWO\
younger than those wiWKWKH%ȕ$UJYDULDQW which may indicate premature mortality in 
this population. InterestinglyWKH\RXQJHUDJHRIFDUULHUVRI%ȕ/\VYDULDQWRQO\DSSOLHGWR
women, who also demonstrated an increased risk of cerebrovascular events in carriers of 
this polymorphism. This further suggests a gender difference in the interaction between the 
polymorphism and fibrin-related thrombosis risk in individuals with T2DM. Similar gender-
VSHFLILFDVVRFLDWLRQEHWZHHQVWURNHDQG%ȕ/\VYDULDQWRIILEULQRJHQKDVEHHQ
documented in a non-diabetic population before (20) and this therefore requires further 
investigation. However, we should be cautious in our interpretations as the study was not 
powered to investigate a clinical effect of this polymorphism. Whilst the difference in age was 
statistically significant, the potential survival benefit with the Arg448 variant is relatively 
modest and future research is needed to clarify whether this polymorphism has a more 
deleterious effect in particular subgroups of patients with diabetes. These findings are 
therefore merely hypothesis-generating and require further investigation in large longitudinal 
studies. We have further identified differences in ABI, a measure of peripheral vascular 
GLVHDVHDQG%ȕ$UJ/\VJHQHWLFYDULDQWVRIILEULQRJHQZKLFKZDVDJDLQRQO\HYLGHQWLQ
women. The presence of peripheral vascular disease indicates extensive vascular 
SDWKRORJ\VXSSRUWLQJDQDVVRFLDWLRQRI%ȕ/\VZLWKVHYHULW\RIYDVFXODUSDWKRORJ\ 
However, caution should be exercised when interpreting these data, as clinical relevance of 
the documented differences can only be accurately assessed in a longitudinal study that is 
currently ongoing. 
 
In summary, the current work demonstrates that the common genetic variant of 
ILEULQRJHQ%ȕ/\VKDVDQDGGLWLYHHIIHFWRYHUWKDWRI7'0RQILEULQFORWVWUXFWXUHDQG
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fibrinolysis. Moreover, RXUGDWDVXJJHVWDQLQWHUDFWLRQEHWZHHQ%ȕ$UJ/\VYDULDQWVRI
fibrinogen, gender and clinical vascular disease that requires further investigation. Overall, 
this study indicates an important role for fibrinogen gene variants in determining thrombosis 
risk even in a complex multifactorial condition such as T2DM. Further clinical studies are 
needed to investigate the role of this common polymorphism in vascular risk in diabetes, 
which may lead to individualised therapies to reduce cardiovascular events, the main cause 
of mortality in this population. 
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Table I. Clinical characteristics DQGSURWHLQOHYHOVLQFDUULHUVRI%ȕ$UJ/\VYDULDQWV
of fibrinogen. 7KH%ȕ$UJgroup consists of homozygotes for the %ȕ$UJ fibrinogen 
variant. The %ȕ448Lys group consists of homozygotes for the %ȕ448Lys fibrinogen variant 
plus all heterozygotes. SD, standard deviation; T2DM, type 2 diabetes; ACEi, angiotensin-
converting-enzyme inhibitor; ARB, angiotensin receptor blocker. 
 
Figure 1. %ȕ$UJ/\VJHQHWLFYDULDQWVRIILEULQRJHQDQGSODVPDILEULQQHWZRUNVThe 
%ȕ$UJgroup consists of homozygotes for the %ȕ$UJ fibrinogen variant. The 
%ȕ448Lys group consists of homozygotes for the %ȕ448Lys fibrinogen variant plus all 
heterozygotes. The following clot structure parameters are shown: (A) Lag time; no 
significant difference with BE448 allele (B) Lysis time; significant increase with BE448Lys 
variant and (C) Maximum absorbance; significant increase with BE448Lys variant. Data 
presented are mean ± SD. 
 
Figure 2. %ȕ$UJ/\VJHQHWLFYDULDQWVDQGILEULQFORWVSUHSDUHGIURPSXULILHG
fibrinogen. (A) Clot maximum absorbance; significant decrease with increasing copies of 
the 448Lys allele. (B) Lysis time; prolongation with increasing copies of the 448Lys allele. 
Data presented are mean ± SD. 
 
Figure 3. 9LVXDOLVDWLRQRIILEULQFORWVSUHSDUHGIURP%ȕ$UJ/\VJHQHWLFYDULDQWVRI
fibrinogen using purified protein. (A) Laser scanning confocal microscopy (magnification 
x4000), showing more compact clots with increasing copies of BE448Lys allele. Scale bars 
represent 50PM. (B) Scanning electron micrographs (magnification x30000), demonstrating 
differences in clot structure with the genetic variants of fibrinogen. Scale bars represent 
3PM. (C) Fibre thickness showing a decrease with increasing copies of BE448Lys allele. 
Data presented are mean ± SD. 
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Figure 4. %ȕ$UJ/\VILEULQRJHQYDULDQWVDQGDJHLQLQGLYLGXDOVZLWKW\SHGLDEHWHV
7KH%ȕ$UJgroup consists of homozygotes for the %ȕ$UJ fibrinogen variant. The 
%ȕ448Lys group consists of homozygotes for the %ȕ448Lys fibrinogen variant plus all 
heterozygotes. $3DWLHQWVZLWKWKH%ȕ/\VYDULDQWZHUHVLJQLILFDQWO\\RXQJHUWKDQWKose 
ZLWKWKH%ȕ$UJYDULDQW%:KHQVSOLWIRUJHQGHUWKHDJHGLIIHUHQFHFRPSDULQJWKHWZR
genetic variants of fibrinogen significance was only relevant in women. Data presented are 
mean ± SD.  
 
)LJXUH3UHGLFWLYHYDOXHRI%ȕ$UJ/\VILEULQRJHQYDULDQWVIRUFHUHEURYDVFXODU
disease. 7KH%ȕ$UJgroup consists of homozygotes for the %ȕ$UJ fibrinogen variant. 
The %ȕ448Lys group consists of homozygotes for the %ȕ448Lys fibrinogen variant plus all 
heterozygotes. %ȕ/\VILEULQRJHQwas associated with a history of cerebrovascular 
disease in the whole group, which was evident in women only after repeating the analysis by 
gender. Model adjusted for cardiovascular risk factors including total and high density 
lipoprotein cholesterol, HbA1c, systolic and diastolic blood pressure and smoking. Data 
displayed as OR ± 95% CI. OR, odds ratio. 
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Table I 
Variable %ȕ$UJ 
(n=564) 
%ȕ/\V 
(n=258) 
p-value 
Age, years (range) 68.3 (60±75) 67.6 (60±75) 0.02 
Duration of T2DM, years (±SD) 8.05 (6.57) 8.21 (6.32) 0.78 
Current smokers, n (%) 
Males, n (%) 
71 (12.6) 
293 (52.0) 
36 (14.0) 
129 (50.0) 
0.67 
0.60 
 
Vascular parameters 
   
Systolic blood pressure, mmHg 
(±SD) 
133.6 (16.6) 132.2 (15.80) 0.21 
Diastolic blood pressure, mmHg 
(±SD) 
69.0 (8.9) 68.5 (8.6) 0.43 
 
Anthropometrics 
   
Body-mass index, kg/m2, (±SD) 31.0 (5.4) 31.9 (5.8) 0.28 
Waist circumference, cm (±SD) 106.3 (13.0) 107.6 (12.5) 0.15 
Waist/hip ratio (±SD) 0.96 (0.08) 0.96 (0.07) 0.77 
 
Metabolic and renal 
   
HbA1c, %/ mmol/mol, (±SD) 7.4 (1.16)/ 57 (134) 7.4 (1.02)/ 57 (11) 0.90 
Plasma glucose, mmol/l (±SD) 7.48 (2.03) 7.62 (1.93) 0.34 
Total cholesterol, mmol/l (±SD) 4.3 (0.88) 4.3 (0.9) 0.76 
High-density lipoprotein 
cholesterol, mmol/l (±SD) 
1.3 (0.35) 1.3 (0.36) 0.37 
Estimated glomerular filtration 
rate, ml/min/m2 (±SD) 
64.4 (14.49) 63.6 (14.4) 0.44 
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Treatment,  
   
Metformin, n (%) 344 (61.0) 142 (55.0) 0.48 
Aspirin, n (%) 364 (64.5) 171 (66.3) 0.82 
Insulin, n (%) 57 (10.1) 33 (12.8) 0.31 
Thiazolidinediones, n (%) 93 (16.5) 45 (17.4) 0.78 
ACEi & ARB, n (%) 383 (67.9) 174 (67.4) 0.95 
Statins, n (%) 477 (84.6) 211 (81.8) 0.76 
Sulfonylureas, n (%) 180 (31.9) 69 (26.7) 0.27 
Nitrates, n (%) 99 (17.6) 44 (17.1) 0.88 
 
